Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Tumor-Agnostic 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms 1Neuralgia 1Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Telmisartan × Clear all
NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Tanta University

Phase 1/2 Not yet recruiting
36 enrolled
Breast

Breast Neoplasms

NCT06815497 2026-01-28

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT06168487 2025-08-21

Telmisartan in Prostate Cancer

Dartmouth-Hitchcock Medical Center

Phase 1 Recruiting
36 enrolled
Genitourinary

Prostatic Neoplasms

NCT05322889 2024-08-28

PrevTel

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Phase 2 Completed
35 enrolled
BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

Completed
1,165,781 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡